Advertisement

News Stories

May, 2019

WAYLIVRA, the only therapy available for Familial Chylomicronemia Syndrome (FCS), has been authorized as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis whose response to diet and triglyceride-lowering therapy has been inadequate, according to a May 7 press release issued by Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.

0
No votes yet
Name: NLA News
May, 2019

MIAMI, Fla. – (May 16, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.

0
No votes yet
Name: NLA News
May, 2019

MIAMI, Fla. – (May 16, 2019) – The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. 

0
No votes yet
Name: Top Stories

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service